dofequidar has been researched along with Leukemia, Myeloid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuruo, T | 1 |
| Kobayashi, M; Maekawa, M; Matsui, H; Naito, K; Ohnishi, K; Ohno, R; Shigeno, K; Shinjo, K; Takeshita, A; Tanimoto, M; Yamakawa, Y | 1 |
1 review(s) available for dofequidar and Leukemia, Myeloid
| Article | Year |
|---|---|
[Development of drugs to overcome drug resistance--basic approaches].
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Drug Resistance, Multiple; Humans; Leukemia P388; Leukemia, Myeloid; Mice; Mice, Nude; Quinolines; Tumor Cells, Cultured; Verapamil | 1995 |
1 other study(ies) available for dofequidar and Leukemia, Myeloid
| Article | Year |
|---|---|
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cyclosporins; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Immunotoxins; Leukemia, Myeloid; Male; Middle Aged; Quinolines; Sialic Acid Binding Ig-like Lectin 3; Tumor Cells, Cultured | 2002 |